This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2022
ASCO GU 2022
Prostate Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO GU 2022 Kidney Cancer
Viewing 21-40 of 43 articles
ASCO GU 2022: Real-World Experience of Axitinib As Second-Line Treatment in Metastatic Renal Cell Carcinoma: Analysis of the Swedish Population
ASCO GU 2022: Avelumab Plus Axitinib in Advanced Renal Cell Carcinoma: 12-Month Interim Results From a Real-World Observational Study in the United Kingdom
ASCO GU 2022: Pembrolizumab As Post Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Results From 30-Month Follow-Up of KEYNOTE-564
ASCO GU 2022: Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Avelumab/Axitinib in Patients With Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy (NeoAvAx)
ASCO GU 2022: Final Analysis of a Non-Interventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy (CaboCHECK)
ASCO GU 2022: PIVOT IO 011: A Phase 1/2 Study of Bempegaldesleukin Plus Nivolumab and TKI Versus Nivolumab and TKI Alone in Patients With Previously Untreated Advanced or mRCC
ASCO GU 2022: Molecular Alterations Across Sites of Metastasis in Patients With RCC
ASCO GU 2022: Real-Word Evidence in Patients Treated With Pazopanib for Advanced/Metastatic Renal Cell Carcinoma: The APOLON Study
ASCO GU 2022: TiNivo-2: Comparing Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
ASCO GU 2022: Association Between Biomarkers and Clinical Outcomes of Lenvatinib + Pembrolizumab in Advanced Renal Cell Carcinoma: Results From Study 111/KEYNOTE-146
ASCO GU 2022: The Impact of Baseline Peripheral Cytokines on Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With Nivolumab: NIVOREN GETUG-AFU 26 Translational Study
ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib Versus Sorafenib in Relapsed/Refractory Advanced RCC
ASCO GU 2022: Real-World Treatment Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
ASCO GU 2022: Phase II Trial of Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab/nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
ASCO GU 2022: Novel Predictive Biomarkers of Response to Immune Checkpoint Blockade with Nivolumab ± Ipilimumab in the TITAN-RCC Phase 2 Trial
ASCO GU 2022: Health-Related Quality of Life in Previously Untreated Patients with Advanced RCC in CheckMate 214: Five-Year Follow-up Results
ASCO GU 2022: Comprehensive Genomic Profiling of Chromophobe RCC Compared With Non-Chromophobe RCC: Impact of FLCN Genomic Alteration Status
ASCO GU 2022: A Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
ASCO GU 2022: ORCHID: A Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP1 or Other DNA Repair Gene Mutations
ASCO GU 2022: Real-World Assessment of Changing Treatment Patterns and Sequence for Patients With Metastatic RCC in the First-Line Setting
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free